<DOC>
	<DOCNO>NCT02728531</DOCNO>
	<brief_summary>Given establish role high dose cytarabine ( HiDAC ) combine rituximab , along recent data show encouraging efficacy bendamustine , investigator seek integrate synergistic effect medicine alternate cycle induction therapy prior autologous stem cell transplant ( ASCT ) . Based prior experience bendamustine rituximab ( BR ) base induction therapy , investigator seek evaluate efficacy safety stem cell mobilization pilot study</brief_summary>
	<brief_title>Bendamustine Rituximab Alternating With Cytarabine Rituximab Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm mantle cell lymphoma document expression CD20 ( CD 19 ) cyclin D1 ( BCL1 ) immunohistochemical stain and/or ( 11 ; 14 ) cytogenetics FISH Eighteen 65 year age , inclusive . Presence evaluable disease PET image per Lugano classification ( Cheson 201418 ) Eligible autologous stem cell transplantation . ECOG performance status ≤ 2 Normal bone marrow organ function define : Absolute neutrophil count ≥ 1,000/mcl unless opinion treat physician , neutropenia due splenomegaly bone marrow involvement Platelets ≥ 100,000/mcl unless opinion treat physician , thrombocytopenia due splenomegaly bone marrow involvement Total bilirubin ≤ 2 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 3.0 x IULN except , opinion treat physician , due direct involvement lymphoma ( e.g. , hepatic infiltration biliary obstruction due lymphoma ) Gilbert 's disease Creatinine ≤ IULN OR creatinine clearance ≥ 40 mL/min/1.73 m2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Negative HIV serology . Any previous chemotherapy radiation mantle cell lymphoma . Short course steroid symptom relief prior presentation permissible . Symptomatic meningeal parenchymal brain lymphoma . A history allergic reaction attribute compound similar chemical biologic composition rituximab , cytarabine , bendamustine agent use study . Severe concurrent illness , would limit compliance study requirement . Subjects serologic status reflect active viral hepatitis B C infection eligible . Subjects whoare hepatitis B core antibody positive antigen negative need negative polymerase chain reaction ( PCR ) prior enrollment . Hepatitis B surface antigen positive PCR positive patient exclude . Subjects hepatitis C antibody positive need negative PCR prior enrollment . Patients positive hepatitis C exclude . Pregnant and/or breastfeeding . Women childbearing potential must negative serum urine pregnancy test within 14 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>